AMP deaminase isoforms purified from endogenous sources display smaller than predicted subunit molecular masses, whereas baculoviral expression of human AMPD1 (isoform M) and AMPD3 (isoform E) cDNAs produces full-sized recombinant enzymes. However, nearly 100 N-terminal amino acid residues are cleaved from each recombinant polypeptide during storage at 4°C. Expression of N-truncated cDNAs (⌬L96AMPD1 and ⌬M90AMPD3) produces stable recombinant enzymes exhibiting subunit molecular masses and kinetic properties that are similar to those reported for purified isoforms M and E. Conversely, wild type recombinant isoforms display significantly higher K m(app) values in the absence of ATP. Gel filtration analysis demonstrates native tetrameric structures for all recombinant proteins, except the wild type AMPD1 enzyme, which forms aggregates of tetramers that disperse upon cleavage of N-terminal residues at 4°C. These data: 1) confirm that available literature on AMP deaminase is likely derived from N-truncated enzymes and 2) are inconsistent with a new model proposing native trimeric structure of an N-truncated rabbit skeletal muscle AMP deaminase (Ranieri-Raggi, M., Montali, U., Ronca, F., Sabbatini, A., Brown, P. E., Moir, A. J. G., and Raggi, A. (1997) Biochem. J. 326, 641-648). N-terminal residues also influence actomyosin-binding properties of the enzyme, which are enhanced and suppressed by AMPD1 and AMPD3 sequences, respectively. Finally, co-expression of AMPD1 and AMPD3 recombinant polypeptides produces tetrameric enzymes with either isoform-specific or mixed subunits, and also reveals that tetramer assembly is driven by relative polypeptide abundance with no apparent preference for like subunits.
AMP deaminase (AMPD 1 ; EC 3.5.4.6) is a diverse tetrameric enzyme that catalyzes a branchpoint reaction in the adenylate catabolic pathway. AMPD plays important biochemical and physiological roles in energy metabolism by competing with cytosolic 5Ј-nucleotidases for available AMP. Multiple AMPD isoforms have been purified and characterized from rat and human tissues and cells (1, 2) and are encoded by transcripts produced from a multigene family (3) (4) (5) (6) (7) . Alignments of predicted primary amino acid sequence across the human AMPD multigene family reveal divergent N-terminal and conserved C-terminal domains (8, 9) . However, cDNA sequences indicate polypeptides with greater subunit molecular masses than those typically observed in enzymes purified from endogenous sources. For example, highly conserved rat and human AMPD1 cDNAs predict polypeptides with subunit molecular masses of 87 kDa (10) , whereas AMPD activities purified from rat (11) (12) (13) , rabbit (13) (14) (15) , and human (2, 16) skeletal muscle exhibit subunit molecular masses ranging from 60 to 72 kDa. Larger subunit molecular masses are observed when purifications are performed in the presence of protease inhibitors, but subsequent degradation occurs upon storage at 4°C (17, 18) . In controlled experiments, limited tryptic digestion of rabbit skeletal muscle AMPD produces an enzyme comprising subunits truncated to leucine residue 96, exhibiting kinetic and electrophoretic properties that are similar to the endogenous enzyme stored at 4°C (15, 19) . This implies, but does not demonstrate, that N-terminal tryptic proteolysis may be responsible for smaller subunit molecular masses of purified AMPD enzymes.
Availability of molecular reagents for the various gene-specific products of the mammalian AMPD multigene family should facilitate the characterization of this diverse enzyme through the production of wild type and genetically modified recombinant activities. Previously, prokaryotic expression of human and rodent AMPD1 and AMPD3 cDNAs has produced AMPD activities that are immunologically similar to the purified endogenous enzymes (20 -23) . However, extensive characterization of these mammalian AMPD recombinant activities has been limited by their low yields in bacterial cells, i.e. Յ0.2 unit/mg of soluble protein. This report demonstrates that baculoviral expression and co-expression of wild type and N-truncated human AMPD1 and AMPD3 recombinant proteins produces much greater amounts of enzyme. Partial purification and characterization of these activities provides insight regarding the role of divergent N-terminal domains of AMPD isoforms on the physical, catalytic, and actomyosin binding properties of the enzyme.
EXPERIMENTAL PROCEDURES
Materials-Grace's insect cell culture medium and fetal bovine serum were obtained from Life Technologies, Inc. Phosphocellulose resin (P-11) was purchased from Whatman Ltd. Gel filtration chromatography resin (Sephacryl S-300HR) and a globular protein standard calibration kit were supplied by Amersham Pharmacia Biotech. Disposable glass columns (1.5 ϫ 30 cm), a protein assay kit, and a silver stain kit were purchased from Bio-Rad. Chemiluminescent reagents used in Western blot analysis were obtained from Amersham Pharmacia Biotech. All chemicals and other reagents were of the highest quality available.
Construction of Baculoviral Expression Plasmids-Wild type and modified AMPD cDNAs were cloned into the baculoviral transfer vector, pBlueBacIII (pBBIII; Invitrogen). Human wild type AMPD1 cDNA (10) was cloned into the BamHI polycloning site of this vector. Human wild type AMPD3 cDNA was cloned into the NcoI (5Ј)/HindIII (3Ј) polycloning sites as described previously (7) . Oligonucleotide-directed PCR mutagenesis was used to produce the following changes in cDNA sequences. 1) A ⌬L96AMPD1 cDNA was constructed using a 28-mer oligonucleotide designed to include created sequence (lowercase) containing an NcoI restriction endonuclease site (underlined) fused to sense strand sequence (uppercase) immediately upstream of the L96 codon (italicized), 5Ј-ctggatccatggAACTGTCCCACATTGA-3Ј. This primer was used in a PCR reaction with a 17-mer antisense oligonucleotide that spanned a downstream NspI restriction endonuclease site (underlined), 5Ј-AGGAACTTCAGGCGCCG-3Ј, in the AMPD1 cDNA. The resultant 520-base pair PCR product was digested with NcoI and NspI, ligated onto the 3Ј-end of the wild type sequence (NspI/HindIII (pBBIII polycloning site)), and subcloned back into NcoI/HindIII-digested pBBIII. The predicted protein encoded by this recombinant insert has two additional residues (Met and Glu) at the N terminus of the ⌬L96 polypeptide. 2) A ⌬M90AMPD3 cDNA was constructed using a 27-mer oligonucleotide designed from sense strand sequence to create a BamHI restriction endonuclease site (underlined; mutations boldface) upstream of the M90 codon, 5Ј-GTTTCAAGAGGATCCGGTCCCAGT-CCC-3Ј. This primer was used in a PCR reaction with a downstream 17-mer antisense oligonucleotide, 5Ј-AGGACTGCGGCCGTAGA-3Ј. The PCR product was digested with BamHI and SmaI and subcloned into the existing wild type AMPD3 baculoviral transfer vector after removing the corresponding BamHI (5Ј-polycloning site)/SmaI fragment representing the 5Ј end of the wild type sequence. For the coexpression of AMPD cDNAs, human wild type AMPD1 and AMPD3 cDNAs were subcloned into the dual promoter baculoviral transfer vector, p2Bac (Invitrogen). The AMPD1 cDNA was put into the SmaI (5Ј)/SpeI (3Ј) polycloning sites immediately downstream of the P10 promoter, and the AMPD3 cDNA was placed into the NcoI (5Ј)/HindIII (3Ј) polycloning sites immediately downstream of the polyhedrin promoter.
Insect Cell Transfection and Production of High Titer Baculoviral Supernatants-Sf9
(Spodoptera frugiperda) cells were maintained and propagated at 27°C in Grace's insect cell medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum. Each expression plasmid was co-transfected with a modified baculoviral genome (BaculoGold; PharMingen) into Sf9 cells according to a calcium phosphatemediated protocol recommended by the supplier. Plaques were visualized 10 -14 days after overlaying serial dilutions of transfected cells with soft agar. Isolated plaques were amplified by consecutive passage through Sf9 cells until high titer viral supernatants (Ͼ10 7 plaque-forming units/ml) were achieved.
AMP Deaminase Assay-AMP deaminase assays were performed at 37°C in 25 mM imidazole, pH 6.5 (AMPD1), pH 6.7 (AMPD1/AMPD3), or pH 7.0 (AMPD3), containing 150 mM potassium chloride. Where indicated, 2 mM ATP was also included in the assay. Substrate (AMP) and product (IMP) were monitored by anion-exchange high performance liquid chromatography, as described previously (24) .
Expression and Phosphocellulose Purification of AMPD Recombinant Enzymes-Sf9 cells were seeded into 6 -16 T-185 flasks and infected at 60 -80% confluence with high titer supernatants (multiplicity of infection ϳ5) of recombinant baculovirus. Infected cells were incubated at 27°C and harvested 72-96 h after infection by scraping into ice-cold extraction buffer (20 mM potassium phosphate, pH 6.5 (AMPD1) or pH 7.0 (AMPD3), containing 100 mM potassium chloride and 0.1% ␤-mercaptoethanol). Detached cells were recovered from the medium by centrifugation at 500 ϫ g for 6 min at 4°C and resuspended in the harvested cell suspension. Cells were disrupted by sonication on ice, and the extract was clarified by centrifugation at 13,000 ϫ g for 5 min at 4°C. The crude extract was batch adsorbed for 30 min at 4°C with gentle rotation to phosphocellulose resin (Whatman P-11) equilibrated in fresh extraction buffer. Adsorbed resin was washed twice with fresh extraction buffer and poured into a pre-cooled glass column (1.5 ϫ 30 cm). Protein was eluted with a 100-ml salt gradient (0.1-2 M potassium chloride), and 2-ml fractions were collected and monitored for protein and AMPD activity. Active fractions were stored at 4°C or at Ϫ80°C after the addition of glycerol to 50% (v/v). The following modifications were made when co-expressing AMPD1 and AMPD3 cDNAs. 1) Extraction buffer was 20 mM potassium phosphate, pH 6.7, containing 200 mM potassium chloride and 0.1% ␤-mercaptoethanol; 2) protein was eluted with a 250-ml salt gradient (0.2-0.9 M potassium chloride).
Polyacrylamide Gel Electrophoresis-Peak phosphocellulose fractions of human AMPD recombinant activities were fractionated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) according to the method of Laemmli (25) . 9% SDS-PAGE gels were fixed and stained with either Coomassie Blue R or silver nitrate.
N-terminal Sequence Analysis-Wild type human AMPD recombinant polypeptides and smaller products resulting from storage of phosphocellulose-purified fractions at 4°C (see "Results") were resolved by 6% SDS-PAGE and electroblotted onto polyvinylidene difluoride membranes using 22.5 mM N-ethylmorpholine, pH 8.3 (26) . Bands of electroblotted proteins were visualized with Amido Black stain, excised, and inserted into a Beckman/Porton model LF3000 gas phase sequencer. Samples were sequenced using conventional Edman sequence chemistry. Data were reported using the Beckman System Gold software, and background corrections were made manually. N-terminal protein sequencing was performed by the Protein/Nucleic Acid Shared Facility of the Medical College of Wisconsin.
Gel Filtration Chromatography-Phosphocellulose-purified AMPD recombinant enzymes were dialyzed overnight at 4°C against 1000 volumes of 50 mM imidazole, pH 6.5 (AMPD1), pH 6.7 (AMPD1/ AMPD3), or pH 7.0 (AMPD3), containing 500 mM potassium chloride and 1 mM dithiothreitol, then passed over a 1 ϫ 90-cm glass column packed with Sephacryl S-300HR resin (Amersham Pharmacia Biotech; exclusion volume Ͼ2000 kDa) equilibrated in dialysis buffer. Eluant was collected (0.5 ml), and elution volumes (V e ) were determined for each enzyme by monitoring AMPD activity. The void volume (V o ) of the column was determined by the relative elution of blue dextran, and the resolving range of the resin was standardized using known globular proteins.
Actomyosin Binding Assay-Purified adult rat skeletal muscle actomyosin was prepared free of endogenous AMPD activity by phosphate extraction. A modification of a previously described in vitro binding assay (27) was used to assess relative binding capacities of AMPD recombinant enzymes for skeletal muscle actomyosin. Briefly, 0.23 unit of each recombinant enzyme was mixed at room temperature with 60 g of actomyosin. The mixture was then diluted 9-fold with 62.5 mM imidazole, pH 6.5 (AMPD1), pH 6.7 (AMPD1/AMPD3), or pH 7.0 (AMPD3) (preliminary experiments determined that relative binding capacities were similar at each pH), to reduce the potassium chloride concentration to Ͻ100 mM. Actomyosin was precipitated by centrifugation at 13,000 ϫ g at 4°C for 10 min. Pellets were washed twice without perturbation in 50 mM imidazole buffer containing 100 mM potassium chloride, 10 mM glutathione, and 0.1% ␤-mercaptoethanol, then resuspended in 50 mM imidazole buffer containing 500 mM potassium chloride. Aliquots of the diluted mixture before and after centrifugation, and of the resuspended pellet, were assayed for AMPD activity. Parallel mixtures containing either bovine serum albumin or ␥-globulin in place of actomyosin served as nonspecific protein controls in these experiments, which routinely generated less than 1% of AMPD activity in resuspended pellets.
Computer-assisted Kinetic and Statistical Analyses-Computer analyses of kinetic data were performed using a nonlinear regression analysis program, Enzfitter, written by Robin J. Leatherbarrow. Statistical analyses were accomplished using the Instat program software.
RESULTS

Baculoviral Expression and Phosphocellulose Purification of
Wild Type Human AMPD Recombinant Enzymes-AMPD activities of 82-204 milliunits/mg protein have been reported in crude extracts prepared from bacterial cells following expression of wild type mammalian (including human) AMPD1 and AMPD3 cDNAs from prokaryotic vectors (20 -23) . Table I shows that baculoviral expression of human AMPD1 and AMPD3 cDNAs in insect cells produces crude enzyme activities 2-3 orders of magnitude higher than what is achieved in bacteria. AMPD activities have been commonly purified from a wide variety of mammalian tissues using phosphocellulose resin (1, 2, (11) (12) (13) (14) (15) (16) (17) (18) (19) . Moreover, human isoforms can be resolved using a salt gradient to elute them from this adsorption resin, with AMPD3 (isoform E) appearing prior to AMPD1 (isoform M) (2) . Fig. 1 (panels A and B) demonstrates that wild type recombinant enzymes also exhibit this relative elution profile. Moreover, SDS-PAGE analysis of peak active fractions (Fig. 2,  lanes 1 and 4) reveals subunit molecular masses that are similar to those predicted from cDNA sequences (87 kDa, AMPD1; 89 kDa, AMPD3). However, storage at 4°C leads to approxi-mate 10 -11-kDa reductions in subunit molecular masses of both human AMPD recombinant proteins (Fig. 2, lanes 2 and  5) .
N-terminal Sequencing of AMPD Recombinant Polypeptides-N-terminal sequencing was employed to determine if full-sized recombinant enzymes were being isolated, and to gain insight regarding the approximate 10-kDa reductions in their subunit molecular masses during storage at 4°C. Conventional Edman sequencing of wild type AMPD1 and AMPD3 polypeptides yielded no N-terminal sequence, although subsequent amino acid composition analyses were consistent with predictions for full-sized subunits (data not shown). These combined results suggest that both wild type recombinant polypeptides are blocked at their N terminus. Conversely, smaller polypeptides resulting from storage at 4°C generated sequences presented in Fig. 3 . Data are heterogeneous and show that N-terminal portions of both predicted wild type sequences are missing. For AMPD1, approximately three-fourths of Ntruncated polypeptides begin at residue His-98 and the other one-fourth begin at residue Ile-86. For AMPD3, approximately two-thirds of smaller polypeptides begin at residue Met-90 and the other one-third begin at residue Leu-88. Furthermore, the predicted subunit molecular masses for these N-truncated products (AMPD1: ⌬I86, 77 kDa; ⌬H98, 75 kDa; AMPD3: ⌬L88, 79 kDa; ⌬M90, 78 kDa) are consistent with their observed migrations in SDS-PAGE (Fig. 2) .
Baculoviral Expression and Phosphocellulose Purification of N-truncated Human AMPD Recombinant Enzymes-Available
information was used to construct and express N-truncated versions of wild type human AMPD1 and AMPD3 recombinant proteins. 1) ⌬L96AMPD1, designed after a stable tryptic product of the rabbit muscle enzyme (19) , was chosen to model N-truncated isoform M; 2) ⌬M90AMPD3, an N-truncated product of the wild type recombinant enzyme following storage at 4°C, was chosen to model isoform E. Expression and phosphocellulose purification of these two activities are presented in Table I and Fig. 2 . Both modified enzymes elute from phosphocellulose resin at relative positions that are similar to their wild type counterparts, i.e. ⌬M90AMPD3 before ⌬L96AMPD1 (Fig. 1, panels C and D) , and their migration on SDS-PAGE appears nearly identical to the smaller products generated from the wild type proteins following storage at 4°C (Fig. 2,  lane 2 versus 3 and lane 5 versus 6) .
Baculoviral Co-expression of Human AMPD1 and AMPD3 Recombinant Polypeptides-Previous work has resolved five peaks of AMPD activity in both rat brain (28) and human B-lymphoblasts (29) . These activities presumably represent two homotetrameric and three heterotetrameric forms of AMPD2 and AMPD3 polypeptides resulting from their co-expression in the same cell. Fig. 4 (panel A) shows a phosphocellulose elution profile of an adsorbed extract prepared from insect cells following co-expression of wild type human AMPD1 and AMPD3 cDNAs. For comparison, mixed extracts prepared from insect cells infected separately with wild type (Fig. 4,  panel B) or N-truncated (Fig. 4, panel C) human AMPD1 and AMPD3 cDNAs were subjected to the same chromatographic conditions. Two peaks of AMPD activity are observed in the latter analyses, with the AMPD3 activity eluting earlier than the AMPD1 activity in both cases. Conversely, four eluting peaks of activity are apparent in an extract prepared from insects cells following co-expression of wild type human AMPD1 and AMPD3 cDNAs. The first three peaks have intermediate elution volumes, and the fourth co-elutes with AMPD1 activity. Western blot analysis of peak active fractions (Fig. 5) reveals that peaks I-III are hybrid activities formed between AMPD1 and AMPD3 subunits, whereas peak IV comprises solely AMPD1 subunits. Surprisingly, all phosphocellulose-purified AMPD activities resulting from the co-expression of wild type AMPD1 and AMPD3 cDNAs appear to have the smaller, N-truncated subunits.
Catalytic Properties of Human AMPD Recombinant Enzymes-Previous studies of endogenous and recombinant AMPD activities have suggested that N-terminal amino acid residues influence catalytic properties of the enzyme (19, 22) . Therefore, selected kinetic parameters of human wild type and N-truncated AMPD1 and AMPD3 enzymes were investigated. Fig. 4, panel A) behave much like their N-truncated AMPD1 and AMPD3 counterparts.
Gel Filtration Chromatography of Human AMPD Recombinant Enzymes-Native structures of wild type and N-truncated human AMPD recombinant proteins were estimated by gel filtration chromatography. Experimental molecular masses are listed in Table II together with the corresponding predicted masses assuming native tetrameric structures. These data indicate that AMPD recombinant enzymes have native tetrameric structures, with the exception of the wild type AMPD1 activity, which elutes predominantly in the void volume of the column (Fig. 6, panel A) . However, storage at 4°C for 2 months results in the appearance of AMPD1 activity in the resolving range of the resin (panel B) with apparent native and subunit molecular masses of 305 kDa (304 kDa predicted; see Table II) and 76 kDa (panel C), respectively.
Hybrid AMPD1/AMPD3 activities were also analyzed by gel filtration chromatography and all eluted in the resolving range of the resin. These data indicate that AMPD1/AMPD3 hybrid enzymes also have native tetrameric structures. This information may then be used to further interpret the Western blot results shown in Fig. 5 . Peaks I-III are heterotetrameric enzymes with the following subunit compositions: I, 3 AMPD3:1 AMPD1; II, 2 AMPD3:2 AMPD1, III, 1 AMPD3:3 AMPD1. Peak IV is a homotetrameric enzyme comprising AMPD1 subunits.
Actomyosin Binding of Human AMPD Recombinant Enzymes-It is well established that skeletal muscle AMPD (AMPD1) binds reversibly to myofibrillar elements (27, (31) (32) (33) (34) (35) , whereas data are conflicting for other isoforms (32, 33) . Therefore, human AMPD1 and AMPD3 recombinant proteins were assessed for their capacities to co-precipitate with rat skeletal 
Unstable N-terminal Domains in AMPD1 and AMPD3 Enzymes
muscle actomyosin. Fig. 7 summarizes the data and shows that AMPD1 recombinant activities exhibit relative higher actomyosin binding capacities than AMPD3 enzymes. However, the N-terminal region of each wild type recombinant polypeptide appears to have different effects on relative actomyosin binding. Deletion of N-terminal residues diminishes actomyosin binding of the AMPD1 enzyme, whereas the N-truncated AMPD3 activity binds more avidly than its wild type counterpart. The three N-truncated heterotetrameric AMPD1/AMPD3 activities also bind to actomyosin with increasing relative capacities that correlate with the number of AMPD1 subunits in each hybrid enzyme. Finally, the homotetrameric AMPD1 enzyme (peak IV) that is produced in the co-expression system exhibits an actomyosin binding capacity that is nearly identical to the ⌬L96AMPD1 enzyme.
DISCUSSION
AMP deaminase (AMPD) is a highly regulated enzyme that has been purified and characterized from a variety of mammalian tissues and cells. However, subunit molecular masses predicted from cDNA sequences are uniformly larger than those observed in enzymes purified from endogenous sources. Using a baculoviral vector to express human cDNAs in insect cells, it is possible to isolate recombinant AMPD activities that contain apparent full-sized subunits. However, phosphocellulose purification of these activities is not adequate to prevent subsequent reductions in subunit molecular mass during storage at 4°C. These results are reminiscent of those obtained with preparations of rabbit (17, 18) and chicken (18) AMPD1 (isoform M) and AMPD3 (isoform E) recombinant activities following their storage at 4°C: AMPD1, ⌬I86 and ⌬H98; AMPD3, ⌬L88 and ⌬M90. Furthermore, genetically modified enzymes modeled after these N-truncated variants, ⌬L96AMPD1 and ⌬M90AMPD3, exhibit physical and catalytic properties similar to those reported for purified isoforms M (2, 16) and E (2, 30, 36), respectively. Taken together, these results strongly suggest that available literature on purified isoforms M and E have been derived primarily from N-truncated enzymes.
Isolation of AMPD recombinant activities initially comprising apparent full-sized subunits allows in vitro examinations of catalytic and physical properties of the entire enzyme. Unlike their N-truncated variants, wild type human AMPD1 and AMPD3 enzymes exhibit significantly greater K m(app) values in the absence of ATP. This observation reveals a potential mechanism to help preserve adenylate pools during periods of net ATP catabolism. Moreover, wild type AMPD1 recombinant pro- tein exists as a large complex (Ͼ2000 kDa). Because the ⌬L96AMPD1 enzyme has a native tetrameric structure, aggregation of the wild type enzyme comprising apparent full-sized subunits appears attributable to the N-terminal 95 amino acid residues of the polypeptide. This contention is confirmed by data showing that storage of the wild type protein at 4°C results in the appearance of AMPD1 activity with native and subunit molecular masses similar to the ⌬L96AMPD1 enzyme.
AMPD enzymes comprising mixed subunits have been proposed based on the partial characterization of five resolved activities in extracts prepared from rat brain (28) . Three of these activities are precipitated from solution with both antiisoform B (AMPD2) and anti-isoform C (AMPD3) sera. However, neither native structures nor subunit compositions of these presumed hybrid activities have been examined. Recombinant co-expression of human AMPD1 and AMPD3 cDNAs provides a means for extending these previous observations. Combined chromatographic and Western blot analyses show greater relative abundance of AMPD1 polypeptides in this expression system, and under these conditions all AMPD3 polypeptides are assembled into AMPD1/AMPD3 heterotetrameric enzymes. These combined observations indicate that assembly of all tetrameric AMPD enzymes is driven by relative polypeptide abundance with no apparent preference for like subunits.
AMPD1/AMPD3 heterotetrameric enzymes may impact clinical consequences of a prevalent nonsense mutation in the AMPD1 gene, i.e. variable association of an exercise-induced skeletal myopathy (37) and increased survival in congestive heart failure (38) . Many individuals who are homozygous for this mutant AMPD1 allele do not exhibit skeletal myopathy, a clinical outcome that is proposed to be affected by an alternative splicing event that removes the mutation from 0.6 -2% of AMPD1 transcripts (20) . Therefore, these individuals produce small amounts of functional isoform M in their skeletal muscles despite a homozygous mutant genotype. Carriers of the AMPD1 nonsense mutation reportedly have increased survival in congestive heart failure (CHF) compared with those who are homozygous for the normal allele. Clinical divergence in CHF is presumably related to different rates of cardiac adenosine production in these two groups of individuals (38) . AMPD3 is expressed in type I skeletal muscle fibers (7, 39) and in the heart (7), thus creating a potential for assembly of hybrid tetrameric enzymes in these two tissues. Production of AMPD1/AMPD3 enzymes in type I skeletal muscle fibers of individuals with inherited AMPD1 deficiency and in CHF patients would serve to maximize AMPD1 expression and may influence clinical outcomes related to this genetic defect.
Skeletal muscle AMPD (AMPD1) binds reversibly to contractile elements (27, (31) (32) (33) (34) (35) , and this interaction may be important to the physiological regulation of enzyme activity (40) . Information regarding AMPD3 has been conflicting; with one study showing similar binding capacities of adult rat heart (AMPD3) and skeletal muscle (AMPD1) enzymes (32) , and another study revealing very low myosin binding potential of the heart activity (33) . Using an in vitro assay, the present study has demonstrated different skeletal muscle actomyosin binding capacities for human AMPD1 and AMPD3 recombinant proteins and has also revealed divergent effects of their N-terminal regions on this interaction. The N-terminal 95 amino acids in AMPD1 enhance actomyosin binding, whereas the 89 N-terminal residues in AMPD3 diminish this association. These data underscore a structural role for the N-terminal region of the polypeptide in modulating access of a myosinbinding domain located in another part of the molecule. AMPD1/AMPD3 hybrid enzymes also bind to skeletal muscle actomyosin, conferring additional potential relevance to these molecules in the clinical situations described above.
A new model for AMPD quarternary structure has been proposed recently, based on information generated from the purified rabbit skeletal muscle enzyme. A putative skeletal muscle isoform of histidine-proline-rich glycoprotein (HPRG), an abundant plasma protein, co-purifies with rabbit skeletal muscle AMPD containing near full-sized subunits (41) . Limited tryptic digestion reportedly yields a 222-kDa trimeric enzyme comprising 72-kDa subunits truncated to leucine residue 96 (15, 19) . This combined information has been used to develop a model in which one 75-kDa subunit of skeletal muscle HPRG assembles with three 79-kDa AMPD1 subunits to form an observed 309-kDa hybrid tetrameric protein (41) . Subsequent N-terminal proteolysis dissociates the HPRG subunit from the hybrid tetrameric enzyme and produces a trimeric N-truncated AMPD. Therefore, this model suggests that the N-terminal region of rabbit skeletal muscle AMPD plays a structural role in assembly of the hybrid tetramer. Moreover, the HPRG-like polypeptide must outcompete a fourth AMPD subunit during assembly of the hybrid tetramer, or subsequently displace one following assembly of a homotetrameric AMPD1 enzyme.
Available information from a variety of other sources and results presented in this study are not consistent with the trimeric AMPD-monomeric HPRG hybrid model of rabbit skeletal muscle AMPD. Smaller than predicted subunit molecular masses ranging from 60 to 72 kDa are observed when AMPD is purified from rabbit (13, 14) , rat (11-13), and human (2, 16) skeletal muscle. However, native masses ranging from 238 to 328 kDa are approximately 4 times the observed subunit molecular mass in each case. Skeletal muscle AMPD enzymes in all mammalian species, including rabbit, are highly conserved in the N-terminal region of the polypeptide (10, 19) and, thus, are likely to exhibit similar structural features. These combined data strongly suggest that AMPD1 enzymes purified from mammalian skeletal muscle are tetramers comprising proteolyzed subunits. Moreover, the apparent native molecular mass of the ⌬L96AMPD1 enzyme demonstrates that this human recombinant model of the reported trimeric N-truncated rabbit muscle enzyme assembles into a homotetrameric structure. Finally, the removal of up to 98 N-terminal amino acid residues from the wild type AMPD1 recombinant polypeptide during storage at 4°C does not result in a trimeric enzyme. Whereas N-truncated subunits are evident in enzymes purified from endogenous sources, a growing body of evidence suggests that these activities may not accurately reflect physiological behavior of AMPD. Divergent N-terminal domains in AMPD isoforms influence contractile protein-binding properties of the enzyme (Fig. 7) and facilitate regulation by ATP under mildly acidic conditions typical of skeletal muscle exercise (19) . Ongoing studies are aimed at further characterization of divergent N-terminal domains in AMPD isoform function. Using two-tailed t tests: *, p Ͻ 0.05 when compared with all other human AMPD recombinant enzymes; §, p Ͻ 0.05 when compared with all other recombinant enzymes except peak I and peak II; †, p Ͻ 0.05 when compared with wild type AMPD3 and wild type AMPD1 recombinant enzymes; £, p Ͻ 0.05 when compared with wild type AMPD3 recombinant enzyme; ¥, p Ͻ 0.05 when compared with wild type AMPD3 and ⌬M90AMPD3 recombinant enzymes; ¶, p Ͻ 0.05 when compared with wild type AMPD3, ⌬M90AMPD3, and wild type AMPD1 recombinant enzymes; q, p Ͻ 0.05 when compared with all other recombinant enzymes except peak II and peak III.
